Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Celsion Corporation

Market Cap 7.65M 6.67M 6.18M 5.78M 10.84M 722M 10.91M 73.26M 28.39M 355M 28.71M 28.09M 1.23B P/E 2026 *
-0.58x
P/E 2027 * -0.8x
Enterprise Value 7.65M 6.67M 6.18M 5.78M 10.84M 722M 10.91M 73.26M 28.39M 355M 28.71M 28.09M 1.23B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 69 2010-07-07
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-1.25%+64.25%+116.08% 55.19B
+4.60%+3.02%+57.38%+62.27% 45.75B
-1.44%+0.39%-14.68%-15.42% 22.98B
-2.69%-2.10%-6.70%+363.03% 20.76B
-1.43%-1.16%+24.73%-19.05% 16.26B
+0.58%+1.08%+18.85%-36.52% 15.42B
-1.01%-2.30%+28.59%+173.07% 13.05B
+4.95%+11.70%+125.78%+261.94% 12.45B
-5.72%-6.30%+19.90% - 12.37B
Average +0.01%+2.28%+35.34%+113.18% 23.8B
Weighted average by Cap. +0.82%+1.51%+40.01%+104.46%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.31M -13.25M -12.4M -23.26M -1.55B -23.4M -157M -60.92M -762M -61.59M -60.27M -2.65B -23.33M -20.34M -18.84M -17.63M -33.07M -2.2B -33.27M -223M -86.61M -1.08B -87.56M -85.69M -3.76B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!